Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer

Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer

As an ultralow prostate-specific antigen (PSA) nadir (≤0.02 ng/ml) after apalutamide treatment for metastatic hormone-sensitive prostate cancer (mHSPC) was associated with the best oncological outcomes, the question arises as to whether this holds true for both synchronous and metachronous mHSPC. We...

Full description

Saved in:
Bibliographic Details
Main Authors: Mike Wenzel, Thomas Steuber, Carolin Siech, Maximilian Kriegmair, Benedikt Hoeh, Derya Tilki, Axel S. Merseburger, Felix K.H. Chun, Philipp Mandel
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:European Urology Open Science
Subjects:
Metastatic prostate cancer
Mortality
Survival
Hormone-sensitive prostate cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168325001223
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items